GGHC
EBS icon

Gilder Gagnon Howe & Co’s Emergent Biosolutions EBS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,069
Closed -$3.14M – 396
2020
Q4 		$3.14M Sell
35,069
-5,499
-14% -$505K 0.02% 233
2020
Q3 		$4.19M Buy
+40,568
New +$4.37M 0.03% 206

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's EBS Position: Q1 2021 in Review

Gilder Gagnon Howe & Co sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 35,069 shares — an estimated $3.14M sold.

Gilder Gagnon Howe & Co first reported a position in EBS in Q3 2020 and held it in 2 quarters. The position peaked at $4.19M in Q3 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

  • Gilder Gagnon Howe & Co reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 35,069 Emergent Biosolutions shares in Q1 2021, an estimated $3.14M.
  • Gilder Gagnon Howe & Co first reported a position in Emergent Biosolutions in Q3 2020 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Emergent Biosolutions position peaked at $4.19M in Q3 2020.
  • 340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2021, filed 17 May 2021.